Italian Biotech Huyabio Shows HDAC Inhibitor Significantly Boosts Melanoma Immunotherapy Outcomes
Huyabio International reported positive Phase 3 results for its oral HDAC inhibitor HBI-8000 combined with nivolumab, demonstrating higher response rates and longer progression‑free survival in advanced melanoma patients, with a manageable safety profile.